A vaccine helped mice with a hard-to-treat brain tumor live longer
Original title: Vaccination targeting the novel endogenous tumor-associated antigen Gpr149 induces protective immunity against checkpoint inhibitor-refractory SB28 glioblastoma
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This was only done in mice.
The short version
In mice, a new vaccine helped the immune system fight a brain tumor that resists other drugs.
What was studied. Scientists used mice with a brain tumor much like glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary. This tumor does not respond to drugs that unlock the immune system. The team looked for targets on the tumor cells, then built vaccines aimed at those targets.
What they found. They found five possible targets on the tumor. One of them, called Gpr149, caused the strongest immune response. Mice that got the Gpr149 vaccine plus an immune drug lived longer, and 50% of mice lived a long time. Vaccines aimed at the other targets did not help the mice live longer.
What this means, and what it doesn't
What it could mean: This points to one way to train the immune system to attack brain tumor cells. It also gives researchers a better mouse model for testing this kind of vaccine. Any help for people is still far off.
What it doesn't mean: This work was done only in mice, not in people. The target was found in this mouse tumor, so human tumors may not carry the same one. No patient can get this vaccine today. It is not proof that it works in people, and it is not a cure.
Source: bioRxiv (preprint), October 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.